Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

Suvratoxumab

Другие языки:

Suvratoxumab

Подписчиков: 0, рейтинг: 0

Suvratoxumab
Monoclonal antibody
Type	?
Source	Human
Target	Staphylococcus aureus alpha toxin
Clinical data
Other names	MEDI4893
ATC code	none
Identifiers
CAS Number	1629620-18-3
ChemSpider	none
UNII	4L1997J4DF
KEGG	D11124
Chemical and physical data
Formula	C₆₅₅₆H₁₀₁₁₄N₁₇₃₀O₂₁₀₀S₄₄
Molar mass	148179.68 g·mol⁻¹

Suvratoxumab (INN; development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.

This drug was developed by MedImmune

Monoclonal antibodies for infectious disease and toxins

Fungal

Human	Efungumab^†

Viral

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Bacterial

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Toxin

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III